BioCryst
Jump to navigation
Jump to search
BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical company based at 2190 Parkway Lake Drive in Birmingham. The company, which began in 1986, manufactures various types of perscription drugs. Its two most well-known products include a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
The CEO and Chairman of the Board is Dr. Charles E. Bugg, who was one of the companies co-founders in 1986. Set to retire in 2007, under Brugg's leadership, the company went public in 1994 seeing moderate profits.
Products
BioCryst is developing the following drug treatments:
- Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
- Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
- Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
- Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
- BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
- peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
- BCX-4208 Oral, for treatment of Hepatitis C
References
- BioCryst Pharmaceuticals, Inc. (2005) Corporate Report 2005 (PDF) - accessed September 21, 2006
- BioCryst Pharmaceuticals Inc. corporate spotlight at NASDAQ. - Accessed September 21, 2006
- Hubbard, Russell. (September 21, 2006) "BioCryst says CEO will retire in 2007." Birmingham News.
External links
- BioCryst Pharmaceuticals Inc. website